Multiomics Market
完整報告名稱與涵蓋範圍
Multiomics Market by Offerings [Product (Instrument, Kits, Reagents), Service], Method (Epigenomics, Single Cell, Spatial), Technology [Sequencing, Proteomics (NGS, PCR, MS)], Workflow (Sample Prep), Application, Competition - Global Forecast to 2031
報告摘要
The global multiomics market is estimated to reach USD 5.70 billion by 2031 from USD 3.18 billion in 2026, at a CAGR of 12.3% during the forecast period. The global multiomics market is expected to witness significant growth through 2031, driven by the increasing adoption of integrated genomic, transcriptomic, proteomic, metabolomic, and epigenomic profiling technologies. The market expansion is supported by rising demand for comprehensive biological characterization in oncology, drug discovery, precision medicine, and translational research. Advancements in single-cell analysis, spatial omics, next-generation sequencing, mass spectrometry, and AI-enabled bioinformatics platforms are further accelerating adoption. However, high technology costs, complex data integration requirements, and the need for specialized computational expertise may limit adoption across resource-constrained research environments.
“The product segment accounted for the largest share by offering in the multiomics market in 2025.”
Based on offering, the multiomics market is segmented into products and services. In 2025, products accounted for the largest share of the market, driven by widespread adoption of sequencing platforms, analytical instruments, assay kits, reagents, consumables, and software solutions required throughout multiomics workflows. These products support sample preparation, sequencing, characterization, and data analysis activities across pharmaceutical companies, biotechnology firms, academic institutions, and research laboratories. The services segment is expected to grow at the fastest rate during the forecast period, supported by increasing outsourcing of complex multiomics profiling, bioinformatics analysis, and integrated omics interpretation to specialized service providers.
“Single-cell omics accounted for the largest share, by method, in the multiomics market in 2025.”
Based on method, the multiomics market is segmented into epigenomics, single-cell omics, spatial omics, long-read & long-range sequencing, proteomics, and other methods. Single-cell omics accounted for the largest share in 2025 due to its ability to characterize cellular heterogeneity and molecular interactions at individual cell resolution. Increasing adoption in oncology, immunology, developmental biology, and drug discovery applications continues to support its leading position. Spatial omics is expected to register the fastest growth during the forecast period, driven by increasing demand for technologies that preserve tissue architecture while enabling simultaneous molecular profiling.
“The Asia Pacific is growing at the highest CAGR in the multiomics market from 2026 to 2031.”
The multiomics market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. During the forecast period, the Asia Pacific region is expected to register the highest CAGR, driven by increasing investments in genomics and life sciences research, expanding precision medicine initiatives, and the growing adoption of next-generation sequencing (NGS), single-cell, spatial biology, and high-resolution mass spectrometry technologies. Regional growth is further supported by rising government funding for omics research, rapid expansion of biotechnology and pharmaceutical R&D, increasing availability of advanced research infrastructure, and the growing presence of contract research organizations (CROs) and genomic service providers. Additionally, the strong presence of leading regional companies such as BGI Genomics and Novogene, along with continued investments by global multiomics technology providers, is strengthening the region's capabilities in multiomics research, biomarker discovery, and precision medicine applications, making Asia Pacific the fastest-growing market during the forecast period.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side - 70% and Demand Side - 30%
• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: CXOs and Directors - 30%, Managers - 45%, and Others - 25%
• By Region: North America - 40%, Europe - 25%, Asia Pacific - 20%, Latin America - 10%, and the Middle East & Africa - 5%
List of Companies Profiled in the Report
• 10x Genomics, Inc.
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• Oxford Nanopore Technologies plc
• Bruker
• PacBio
• Danaher Corporation
• Vizgen Corporation
• Agilent Technologies, Inc
• Biognosys AG
• Merck KGaA
• QIAGEN N.V.
• Revvity, Inc.
• Waters Corporation
• Syngene International
• Bio-Rad Laboratories, Inc
• Takara Bio Inc
• Metabolon, Inc
• BGI Genomics Co., Ltd
Research Coverage
This research report categorizes the multiomics market by offering, method, technology, workflow, application, end user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the multiomics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product and service approvals and launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the multiomics market. This report covers competitive analysis of top players and upcoming startups in the multiomics market ecosystem.
Key Benefits of Buying the Report
The report will help market leaders/new entrants by providing the closest approximations of revenue for the overall multiomics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
• Analysis of key drivers (rising adoption of multiomics in precision medicine and disease stratification, rapid adoption of single-cell and spatial multiomics, increasing accessibility of high-quality integrated omics data for research, and advances in AI, machine learning, and cloud bioinformatics for cross-omics data interpretation), restraints (complexity of multiomics data integration and standardization, and high costs associated with multiomics technologies limiting widespread adoption), opportunities (growing adoption of spatial proteomics for tissue-context analysis and biomarker discovery, and increasing emergence of single-cell proteomics for high-resolution cellular profiling), and challenges (lack of standardization across multiomics workflows) influencing the growth of multiomics market
• Product Development/Innovation: Detailed insights on newly launched products of the multiomics market
• Market Development: Comprehensive information about lucrative markets – the report analyses the Multiomics market across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the multiomics market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as 10x Genomics, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Oxford Nanopore Technologies plc (UK), and Bruker Corporation (US), among others
授權報價
| Single User Licence | $4,950 USD |
| Multi User Licence | $6,650 USD |
| Corporate User Licence | $8,150 USD |
| Global User Licence | $10,000 USD |
目錄 Table of Contents
1 INTRODUCTION 53
1.1 STUDY OBJECTIVES 53
1.2 MARKET DEFINITION 53
1.3 STUDY SCOPE 53
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 54
1.3.2 INCLUSIONS & EXCLUSIONS 55
1.3.3 YEARS CONSIDERED 56
1.3.4 CURRENCY CONSIDERED 57
1.4 STAKEHOLDERS 57
2 EXECUTIVE SUMMARY 58
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 58
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 60
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 61
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 62
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 63
3 PREMIUM INSIGHTS 64
3.1 MULTIOMICS MARKET OVERVIEW 64
3.2 MULTIOMICS MARKET, BY OFFERING AND REGION 65
3.3 MULTIOMICS MARKET: GEOGRAPHIC SNAPSHOT 66
3.4 MULTIOMICS MARKET, BY OFFERING 66
4 MARKET OVERVIEW 67
4.1 INTRODUCTION 67
4.2 MARKET DYNAMICS 67
4.2.1 DRIVERS 68
4.2.1.1 Rising use of multiomics in precision medicine and disease stratification 68
4.2.1.2 Rapid adoption of single-cell and spatial multiomics 69
4.2.1.3 Increasing accessibility of high-quality, integrated omics data for research 69
4.2.1.4 AI, machine learning, and cloud bioinformatics improving cross-omics interpretation 69
4.2.2 RESTRAINTS 70
4.2.2.1 Complexity of multiomics data integration and standardization 70
4.2.2.2 High costs constrain technology adoption 70
4.2.3 OPPORTUNITIES 70
4.2.3.1 Growing adoption of spatial proteomics for tissue-context analysis and biomarker discovery 70
4.2.3.2 Increasing emergence of single-cell proteomics for high-resolution characterization of cellular profiles 71
4.2.4 CHALLENGES 71
4.2.4.1 Lack of standardization across multiomics workflows 71
4.3 UNMET NEEDS AND WHITE SPACES 71
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 72
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 73
5 INDUSTRY TRENDS 75
5.1 PORTER’S FIVE FORCES ANALYSIS 75
5.1.1 THREAT OF NEW ENTRANTS 76
5.1.2 THREAT OF SUBSTITUTES 76
5.1.3 BARGAINING POWER OF BUYERS 76
5.1.4 BARGAINING POWER OF SUPPLIERS 77
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 77
5.2 MACROECONOMIC OUTLOOK 77
5.2.1 INTRODUCTION 77
5.2.2 GDP TRENDS AND FORECAST 77
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 78
5.2.4 TRENDS IN GLOBAL PHARMACEUTICAL INDUSTRY 78
5.3 VALUE CHAIN ANALYSIS 78
5.4 ECOSYSTEM ANALYSIS 80
5.5 PRICING ANALYSIS 81
5.5.1 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY TYPE (2023–2025) 82
5.5.2 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY TYPE, 2023–2025 83
5.5.3 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 83
5.6 TRADE ANALYSIS 85
5.6.1 IMPORT DATA FOR HS CODE 9027 85
5.6.2 EXPORT DATA FOR HS CODE 9027 86
5.6.3 IMPORT VOLUME FOR HS CODE 9027 87
5.6.4 EXPORT VOLUME FOR HS CODE 9027 87
5.7 KEY CONFERENCES & EVENTS 88
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 89
5.9 INVESTMENT/FUNDING ACTIVITY 90
5.10 CASE STUDY ANALYSIS 90
5.10.1 ADVANCED MULTIOMICS PROFILING TO SUPPORT PRECISION MEDICINE ADOPTION 91
5.10.2 INTEGRATED LONG-READ SEQUENCING TO SUPPORT MULTIOMICS RESEARCH 91
5.10.3 MULTIOMICS DATA INTEGRATION TO ACCELERATE BIOMARKER DISCOVERY 92
5.11 IMPACT OF 2025 US TARIFFS—MULTIOMICS MARKET 92
5.11.1 INTRODUCTION 92
5.11.2 KEY TARIFF RATES 93
5.11.3 PRICE IMPACT ANALYSIS 94
5.11.4 IMPACT ON COUNTRIES/REGIONS 94
5.11.4.1 North America 94
5.11.4.2 Europe 94
5.11.4.3 Asia Pacific 95
5.11.5 IMPACT ON END-USE INDUSTRIES 96
5.11.5.1 Pharmaceutical and biotechnology companies 96
5.11.5.2 Hospitals and diagnostic laboratories 96
5.11.5.3 Academic & research institutes 97
5.11.5.4 CROs & CDMOs 97
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 98
6.1 KEY TECHNOLOGIES 98
6.1.1 SINGLE-CELL MULTIOMICS CO-ASSAYS AND SCALABLE BARCODING 98
6.1.2 SPATIAL MULTIOMICS AND SUBCELLULAR TISSUE MAPPING 98
6.1.3 HIGH-PLEX PROTEOGENOMICS AND NGS/PCR-BASED PROTEIN READOUTS 99
6.2 ADJACENT TECHNOLOGIES 99
6.2.1 MICROARRAYS AND HYBRIDIZATION-BASED PROFILING 99
6.2.2 DIGITAL PATHOLOGY AND ADVANCED SPATIAL IMAGING 99
6.3 COMPLEMENTARY TECHNOLOGIES 100
6.3.1 MICROFLUIDICS, CELL/NUCLEI CAPTURE, AND SAMPLE INDEXING 100
6.3.2 HIGH-RESOLUTION MASS SPECTROMETRY AND ION MOBILITY 100
6.4 TECHNOLOGY/PRODUCT ROADMAP 100
6.5 PATENT ANALYSIS 101
6.5.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR MULTIOMICS PATENTS, 2015–2025 101
6.6 FUTURE APPLICATIONS 102
6.7 IMPACT OF AI/GEN AI ON MULTIOMICS MARKET 103
6.7.1 TOP USE CASES AND MARKET POTENTIAL 104
6.7.2 BEST PRACTICES IN AI-ENABLED MULTIOMICS WORKFLOWS 104
6.7.3 CASE STUDIES OF AI IMPLEMENTATION IN MULTIOMICS MARKET 105
6.7.4 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS 105
6.7.5 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN MULTIOMICS MARKET 105
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 107
7.1 REGIONAL REGULATIONS AND COMPLIANCE 107
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107
7.1.2 INDUSTRY STANDARDS 110
7.2 SUSTAINABILITY INITIATIVES 111
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 111
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 111
8 MULTIOMICS MARKET, BY OFFERING 113
8.1 INTRODUCTION 114
8.2 PRODUCTS 114
8.2.1 CONSUMABLES 117
8.2.1.1 Increasing experiment volumes, higher multiplexing, and recurring reagent requirements support growth 117
8.2.1.2 Assay kits & reagents 120
8.2.1.2.1 Recurring assay consumption, higher multiplexing, and improved low-input performance drive market growth 120
8.2.1.3 Other consumables 122
8.2.2 INSTRUMENTS & SOFTWARE 125
8.2.2.1 Integrated multiomics platforms, automated workflows, and AI-enabled data interpretation strengthen demand 125
8.3 SERVICES 128
8.3.1 RISING OUTSOURCING OF SPECIALIZED PROFILING AND INTERPRETATION TO DRIVE MARKET GROWTH 128
9 MULTIOMICS MARKET, BY TECHNOLOGY 132
9.1 INTRODUCTION 133
9.2 SEQUENCING 133
9.2.1 LONG-READ SEQUENCING 136
9.2.1.1 Nanopore sequencing 139
9.2.1.1.1 Real-time native-molecule analysis, scalable platforms, and integrated genomic–epigenomic readouts are accelerating nanopore sequencing adoption 139
9.2.1.2 SMRT Sequencing 142
9.2.1.2.1 High-accuracy HiFi reads and lower sequencing cost to expand SMRT-based multiomics 142
9.2.2 OTHER SEQUENCING TECHNOLOGIES 145
9.3 PROTEOMICS 148
9.3.1 ADVANCES IN HIGH-SENSITIVITY MASS SPECTROMETRY, SINGLE-CELL ANALYSIS, AND SCALABLE PROTEIN QUANTIFICATION ARE ACCELERATING PROTEOMICS ADOPTION IN MULTIOMICS RESEARCH 148
9.4 OTHER TECHNOLOGIES 151
10 MULTIOMICS MARKET, BY METHOD 154
10.1 INTRODUCTION 155
10.2 SINGLE-CELL OMICS 155
10.2.1 IMPROVED CELL CAPTURE AND GROWING DEMAND TO RESOLVE CELLULAR HETEROGENEITY DRIVE MARKET GROWTH 155
10.2.2 SINGLE-CELL TRANSCRIPTOMICS 158
10.2.2.1 Higher sample throughput, improved cell recovery, and compatibility with fixed clinical samples are expanding single-cell transcriptomics 158
10.2.3 SINGLE-CELL EPIGENOMICS 161
10.2.3.1 Growing interest in gene regulation, chromatin state, and treatment resistance is accelerating single-cell epigenomics research 161
10.2.4 SINGLE-CELL PROTEOMICS 164
10.2.4.1 Ultrasensitive mass spectrometry and higher-throughput protein quantification expanding functional analysis at single-cell resolution 164
10.2.5 SINGLE-CELL GENOMICS 167
10.2.5.1 Improved detection of clonal variation and simultaneous genotype-phenotype analysis are driving single-cell genomics adoption 167
10.2.6 OTHER SINGLE-CELL OMICS 169
10.3 PROTEOMICS 172
10.3.1 MS-BASED PROTEOMICS 175
10.3.1.1 Data-independent acquisition and improved quantitative depth to sustain MS-based proteomics leadership 175
10.3.2 NGS-BASED PROTEOMICS 178
10.3.2.1 Sequencing readouts and ultra-high-plex panels to make NGS-based proteomics the fastest-growing proteomics method 178
10.3.3 PCR-BASED PROTEOMICS 180
10.3.3.1 Sensitive proximity-amplification assays to support targeted, low-volume protein profiling 180
10.3.4 OTHER PROTEOMICS METHODS 183
10.4 SPATIAL OMICS 186
10.4.1 SPATIAL TRANSCRIPTOMICS 189
10.4.1.1 Whole-transcriptome tissue mapping and higher resolution to sustain spatial transcriptomics leadership 189
10.4.2 SPATIAL PROTEOMICS 192
10.4.2.1 Higher-plex imaging and tissue phenotyping to accelerate spatial proteomics adoption 192
10.4.3 SPATIAL EPIGENOMICS 194
10.4.3.1 Mapping regulatory states within tissue to expand spatial epigenomics from early research applications 194
10.4.4 SPATIAL GENOMICS 197
10.4.4.1 In situ variant and copy-number mapping to support spatial genomics growth 197
10.4.5 OTHER SPATIAL OMICS 199
10.5 LONG-READ & LONG-RANGE SEQUENCING 202
10.5.1 IMPROVED STRUCTURAL VARIANT, ISOFORM, AND NATIVE EPIGENETIC RESOLUTION TO ACCELERATE ADOPTION 202
10.5.2 LONG-READ SEQUENCING 205
10.5.2.1 Higher accuracy and throughput to ensure market leadership 205
10.5.3 LONG-RANGE SEQUENCING 208
10.5.3.1 Genome mapping and linked information to improve structural and haplotype characterization 208
10.5.4 OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS 210
10.6 EPIGENOMICS 213
10.6.1 SEQUENCING-BASED EPIGENOMICS 216
10.6.1.1 DNA methylation sequencing 219
10.6.1.1.1 Genome-wide and targeted methylation analysis to sustain the largest sequencing-based epigenomics share 219
10.6.1.2 Chromatin accessibility sequencing 222
10.6.1.2.1 ATAC-seq adoption and regulatory element mapping to make accessibility profiling the fastest-growing epigenomics method 222
10.6.1.3 Histone modification profiling 225
10.6.1.3.1 Lower-input chromatin profiling to broaden analysis of histone-associated regulatory states 225
10.6.1.4 Chromatin interaction analysis 228
10.6.1.4.1 3D genome mapping to connect distal regulatory elements with gene activity 228
10.6.2 OTHER EPIGENOMICS METHODS 231
10.7 OTHER METHODS 234
11 MULTIOMICS MARKET, BY WORKFLOW 237
11.1 INTRODUCTION 238
11.2 SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION 238
11.2.1 HIGHER-THROUGHPUT MOLECULAR PROFILING AND INCREASINGLY SENSITIVE ANALYTICAL PLATFORMS TO STRENGTHEN SEQUENCING AND SAMPLE CHARACTERIZATION WORKFLOWS 238
11.3 SAMPLE PREPARATION 241
11.3.1 IMPROVED SAMPLE PRESERVATION, CELL CAPTURE, AUTOMATION, AND MULTIPLEXING TO EXPAND SCALE AND REPRODUCIBILITY OF MULTIOMICS STUDIES 241
11.4 DATA VISUALIZATION & ANALYSIS 244
11.4.1 AI-ENABLED ANALYTICS AND MULTIMODAL INTEGRATION TO ACCELERATE CONVERSION OF COMPLEX MULTIOMICS DATA INTO BIOLOGICAL INSIGHTS 244
12 MULTIOMICS MARKET, BY APPLICATION 248
12.1 INTRODUCTION 249
12.2 ONCOLOGY 249
12.2.1 GROWING USE OF TUMOR MULTIOMICS FOR BIOMARKER DISCOVERY AND PATIENT STRATIFICATION DRIVES MARKET LEADERSHIP 249
12.3 DRUG DISCOVERY & DEVELOPMENT 252
12.3.1 DATA-DRIVEN TARGET SELECTION AND MECHANISM STUDIES TO MAKE DRUG DISCOVERY FASTEST-GROWING APPLICATION 252
12.4 IMMUNOLOGY 255
12.4.1 LARGE-SCALE IMMUNE PROFILING PROGRAMS TO ACCELERATE MULTIMODAL IMMUNOLOGY RESEARCH 255
12.5 PRECISION MEDICINE 257
12.5.1 INTEGRATED MOLECULAR AND CLINICAL DATA TO EXPAND PATIENT-SPECIFIC DECISION SUPPORT 257
12.6 BIOMARKER DISCOVERY 260
12.6.1 CROSS-OMICS VALIDATION TO IMPROVE BIOMARKER ROBUSTNESS AND CLINICAL RELEVANCE 260
12.7 CELL BIOLOGY 263
12.7.1 HIGHER-RESOLUTION PROFILING OF CELL STATES, INTERACTIONS, AND DIFFERENTIATION PROCESSES EXPANDING ROLE OF MULTIOMICS IN CELL BIOLOGY 263
12.8 TRANSLATIONAL RESEARCH 266
12.8.1 IMPROVED ANALYSIS OF SPECIMENS AND MORE SCALABLE SPATIAL WORKFLOWS ACCELERATE TRANSLATION OF MULTIOMICS DISCOVERIES INTO THERAPEUTIC RESEARCH 266
12.9 NEUROLOGY 269
12.9.1 BRAIN-CELL ATLASES AND SPATIALLY RESOLVED MOLECULAR PROFILING DRIVE UNDERSTANDING OF NEUROLOGICAL DISEASE PROGRESSION AND THERAPEUTIC TARGETS 269
12.10 CLINICAL DIAGNOSTICS 271
12.10.1 GROWING CLINICAL SEQUENCING INFRASTRUCTURE TO SUPPORT MULTIOMICS-RELATED DIAGNOSTIC ADOPTION 271
12.11 OTHER APPLICATIONS 274
13 MULTIOMICS MARKET, BY END USER 277
13.1 INTRODUCTION 278
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 278
13.2.1 EXPANDING PRECISION MEDICINE INITIATIVES ACCELERATE MULTIOMICS ADOPTION 278
13.3 ACADEMIC & RESEARCH INSTITUTES 281
13.3.1 GROWING RESEARCH FUNDING DRIVING MULTIOMICS USAGE AMONG ACADEMIC AND RESEARCH INSTITUTES 281
13.4 CROS & CDMOS 284
13.4.1 OUTSOURCING OF COMPLEX PROFILING AND ANALYTICS TO MAKE CROS & CDMOS THE FASTEST-GROWING END USERS 284
13.5 HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES 287
13.5.1 CLINICAL EVIDENCE AND WORKFLOW STANDARDIZATION TO SUPPORT MEASURED ADOPTION IN HOSPITALS AND LABORATORIES 287
14 MULTIOMICS MARKET, BY REGION 290
14.1 INTRODUCTION 291
14.2 NORTH AMERICA 291
14.2.1 US 298
14.2.1.1 Regulatory acceptance, clinically integrated molecular testing, and population-scale health datasets accelerate multiomics adoption 298
14.2.2 CANADA 304
14.2.2.1 Population-scale precision health initiatives expand integration capacity 304
14.3 EUROPE 310
14.3.1 GERMANY 316
14.3.1.1 Clinical integration of genome sequencing and strong translational research networks drive market growth 316
14.3.2 UK 322
14.3.2.1 Population-scale multimodal datasets, NHS integration, and industry-backed biomarker programs propel market growth 322
14.3.3 FRANCE 327
14.3.3.1 Standardized precision-medicine pathways and strong oncology research networks drive market 327
14.3.4 ITALY 333
14.3.4.1 Shared research infrastructure widening access beyond leading academic centers 333
14.3.5 SPAIN 338
14.3.5.1 Hospital-linked genomics programs support steady adoption of integrated profiling 338
14.3.6 REST OF EUROPE 344
14.4 ASIA PACIFIC 350
14.4.1 CHINA 357
14.4.1.1 Large-scale genomic initiatives and rapid adoption of precision medicine technologies drive growth 357
14.4.2 JAPAN 363
14.4.2.1 Mature biobanks and pharmaceutical research support stable, high-value adoption 363
14.4.3 SOUTH KOREA 368
14.4.3.1 National bio-data infrastructure and digital-health capabilities accelerate multiomics use 368
14.4.4 INDIA 374
14.4.4.1 GenomeIndia and expanding translational capacity propel rapid growth in Indian multiomics market 374
14.4.5 AUSTRALIA 380
14.4.5.1 Mission-led genomics investment strengthens clinical translation and data integration 380
14.4.6 REST OF ASIA PACIFIC 386
14.5 LATIN AMERICA 392
14.5.1 BRAZIL 398
14.5.1.1 Growing genomics infrastructure and increasing precision medicine adoption drive market growth 398
14.5.2 REST OF LATIN AMERICA 403
14.6 MIDDLE EAST 409
14.6.1 GCC COUNTRIES 415
14.6.1.1 Saudi Arabia 421
14.6.1.1.1 Rising healthcare expenditure, expanding genomics research, and investments in precision medicine to propel market 421
14.6.1.2 UAE 427
14.6.1.2.1 Large-scale citizen sequencing moves genomics toward preventive and personalized care 427
14.6.1.3 Rest of GCC Countries 433
14.6.2 REST OF MIDDLE EAST 439
14.7 AFRICA 445
14.7.1 DESPITE EMERGING OPPORTUNITIES, GROWTH REMAINS SLOW DUE TO LIMITED ACCESS TO ADVANCED TECHNOLOGY AND INADEQUATE FUNDING & WORKFORCE 445
15 COMPETITIVE LANDSCAPE 451
15.1 OVERVIEW 451
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 451
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN MULTIOMICS MARKET 451
15.3 REVENUE ANALYSIS, 2021–2025 452
15.4 MARKET SHARE ANALYSIS, 2025 453
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 456
15.5.1 STARS 456
15.5.2 EMERGING LEADERS 456
15.5.3 PERVASIVE PLAYERS 456
15.5.4 PARTICIPANTS 456
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 458
15.5.5.1 Company footprint 458
15.5.5.2 Region footprint 459
15.5.5.3 Offering footprint 459
15.5.5.4 Technology footprint 460
15.5.5.5 Workflow footprint 461
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 462
15.6.1 PROGRESSIVE COMPANIES 462
15.6.2 RESPONSIVE COMPANIES 462
15.6.3 DYNAMIC COMPANIES 462
15.6.4 STARTING BLOCKS 462
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 464
15.6.5.1 Detailed list of key startups/SMEs 464
15.6.5.2 Competitive benchmarking of key startups/SMEs 465
15.7 COMPANY VALUATION AND FINANCIAL METRICS 466
15.7.1 COMPANY VALUATION 466
15.7.2 FINANCIAL METRICS 466
15.8 BRAND/PRODUCT COMPARISON 467
15.9 COMPETITIVE SCENARIO 468
15.9.1 PRODUCT & SERVICE LAUNCHES 468
15.9.2 DEALS 468
15.9.3 EXPANSIONS 469
16 COMPANY PROFILES 470
16.1 KEY COMPANIES 470
16.1.1 10X GENOMICS 470
16.1.1.1 Business overview 470
16.1.1.2 Products & services offered 471
16.1.1.3 Recent developments 473
16.1.1.3.1 Product & service launches 473
16.1.1.3.2 Deals 473
16.1.1.4 MnM view 473
16.1.1.4.1 Key strengths 473
16.1.1.4.2 Strategic choices 474
16.1.1.4.3 Weaknesses and competitive threats 474
16.1.2 THERMO FISHER SCIENTIFIC INC. 475
16.1.2.1 Business overview 475
16.1.2.2 Products & services offered 476
16.1.2.3 Recent developments 478
16.1.2.3.1 Product & service launches 478
16.1.2.3.2 Deals 479
16.1.2.4 MnM view 480
16.1.2.4.1 Key strengths 480
16.1.2.4.2 Strategic choices 480
16.1.2.4.3 Weaknesses and competitive threats 480
16.1.3 ILLUMINA, INC. 481
16.1.3.1 Business overview 481
16.1.3.2 Products & services offered 482
16.1.3.3 Recent developments 484
16.1.3.3.1 Product & service launches 484
16.1.3.3.2 Deals 484
16.1.3.4 MnM view 485
16.1.3.4.1 Key strengths 485
16.1.3.4.2 Strategic choices 485
16.1.3.4.3 Weaknesses and competitive threats 485
16.1.4 OXFORD NANOPORE TECHNOLOGIES PLC 486
16.1.4.1 Business overview 486
16.1.4.2 Products & services offered 487
16.1.4.3 Recent developments 488
16.1.4.3.1 Deals 488
16.1.4.3.2 Expansions 489
16.1.4.4 MnM view 489
16.1.4.4.1 Key strengths 489
16.1.4.4.2 Strategic choices 490
16.1.4.4.3 Weaknesses and competitive threats 490
16.1.5 BRUKER 491
16.1.5.1 Business overview 491
16.1.5.2 Products & services offered 492
16.1.5.3 Recent developments 494
16.1.5.3.1 Product & service launches 494
16.1.5.3.2 Deals 495
16.1.5.4 MnM view 495
16.1.5.4.1 Key strengths 495
16.1.5.4.2 Strategic choices 495
16.1.5.4.3 Weaknesses and competitive threats 495
16.1.6 PACBIO 496
16.1.6.1 Business overview 496
16.1.6.2 Products & services offered 497
16.1.6.3 Recent developments 499
16.1.6.3.1 Product & service launches 499
16.1.6.3.2 Deals 499
16.1.7 DANAHER CORPORATION 501
16.1.7.1 Business overview 501
16.1.7.2 Products & services offered 502
16.1.7.3 Recent developments 504
16.1.7.3.1 Product & service launches 504
16.1.7.3.2 Deals 505
16.1.8 VIZGEN, INC. 506
16.1.8.1 Business overview 506
16.1.8.2 Products & services offered 506
16.1.8.3 Recent developments 508
16.1.8.3.1 Deals 508
16.1.9 AGILENT TECHNOLOGIES, INC. 509
16.1.9.1 Business overview 509
16.1.9.2 Products & services offered 510
16.1.9.3 Recent developments 513
16.1.9.3.1 Product & service launches 513
16.1.9.3.2 Deals 513
16.1.9.3.3 Expansions 514
16.1.10 BIOGNOSYS 515
16.1.10.1 Business overview 515
16.1.10.2 Products & services offered 515
16.1.10.3 Recent developments 516
16.1.10.3.1 Deals 516
16.1.11 MERCK KGAA 517
16.1.11.1 Business overview 517
16.1.11.2 Products & services offered 518
16.1.11.3 Recent developments 520
16.1.11.3.1 Expansions 520
16.1.12 QIAGEN N.V. 521
16.1.12.1 Business overview 521
16.1.12.2 Products & services offered 522
16.1.12.3 Recent developments 523
16.1.12.3.1 Product & service launches 523
16.1.12.3.2 Deals 524
16.1.12.3.3 Expansions 524
16.1.13 REVVITY, INC. 525
16.1.13.1 Business overview 525
16.1.13.2 Products & services offered 526
16.1.13.3 Recent developments 528
16.1.13.3.1 Product & service launches 528
16.1.13.3.2 Deals 528
16.1.14 WATERS CORPORATION 530
16.1.14.1 Business overview 530
16.1.14.2 Products & services offered 531
16.1.14.3 Recent developments 532
16.1.14.3.1 Product & service launches 532
16.1.14.3.2 Deals 533
16.1.14.3.3 Expansions 534
16.1.15 BIO-RAD LABORATORIES, INC. 535
16.1.15.1 Business overview 535
16.1.15.2 Products & services offered 536
16.1.15.3 Recent developments 537
16.1.15.3.1 Product & service launches 537
16.1.15.3.2 Deals 538
16.1.16 TAKARA BIO INC. 539
16.1.16.1 Business overview 539
16.1.16.2 Products & services offered 540
16.1.16.3 Recent developments 542
16.1.16.3.1 Expansions 542
16.1.17 METABOLON, INC. 543
16.1.17.1 Business overview 543
16.1.17.2 Products & services offered 543
16.1.17.3 Recent developments 544
16.1.17.3.1 Product & service launches 544
16.2 OTHER PLAYERS 545
16.2.1 BGI GENOMICS CO., LTD. 545
16.2.2 NOVOGENE CO., LTD. 546
16.2.3 AZENTA, INC. 548
16.2.4 EVOTEC SE 549
16.2.5 MEDGENOME LABS LTD. 550
16.2.6 CD GENOMICS 551
16.2.7 BIOGENITY 552
16.2.8 SAPIENT BIOANALYTICS, LLC 553
16.2.9 RAYBIOTECH, INC. 554
16.2.10 SOURCE BIOSCIENCE LTD. 555
17 RESEARCH METHODOLOGY 556
17.1 RESEARCH DATA 556
17.1.1 SECONDARY DATA 557
17.1.2 PRIMARY DATA 557
17.2 MARKET ESTIMATION METHODOLOGY 559
17.2.1 MARKET SIZE ESTIMATION 559
17.2.2 INSIGHTS OF PRIMARY EXPERTS 562
17.2.3 TOP-DOWN APPROACH 562
17.3 MARKET GROWTH RATE PROJECTIONS 563
17.4 MARKET BREAKDOWN AND DATA TRIANGULATION 565
17.5 RESEARCH ASSUMPTIONS 566
17.6 RESEARCH LIMITATIONS 566
17.7 RISK ANALYSIS 567
18 APPENDIX 568
18.1 DISCUSSION GUIDE 568
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 573
18.3 CUSTOMIZATION OPTIONS 574
18.4 RELATED REPORTS 575
18.5 AUTHOR DETAILS 576
圖表清單 List of Tables & Figures
TABLE 1 MULTIOMICS MARKET: IMPACT ANALYSIS 68
TABLE 2 MULTIOMICS MARKET: PORTER’S FIVE FORCES ANALYSIS 76
TABLE 3 MULTIOMICS MARKET: ROLE IN ECOSYSTEM 81
TABLE 4 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY TYPE, 2023–2025 (USD) 82
TABLE 5 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY TYPE, 2023–2025 (USD) 83
TABLE 6 AVERAGE SELLING PRICE TREND OF INSTRUMENTS,
BY REGION, 2023–2025 (USD) 83
TABLE 7 AVERAGE SELLING PRICE TREND OF CONSUMABLES,
BY REGION, 2023–2025 (USD) 84
TABLE 8 IMPORT DATA FOR HS CODE 9027, 2021–2025, (USD THOUSAND) 85
TABLE 9 EXPORT DATA HS CODE 9027, 2021–2025 (USD THOUSAND) 86
TABLE 10 IMPORT VOLUME HS CODE 9027, 2021–2025 (TONS) 87
TABLE 11 EXPORT VOLUME HS CODE 9027, 2021–2025 (TONS) 87
TABLE 12 MULTIOMICS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 88
TABLE 13 US-ADJUSTED RECIPROCAL TARIFF RATES 93
TABLE 14 INDICATIVE LIST OF PATENTS IN MULTIOMICS MARKET, 2025–2026 102
TABLE 15 CASE STUDIES OF AI IMPLEMENTATION IN MULTIOMICS MARKET 105
TABLE 16 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN MULTIOMICS MARKET 106
TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107
TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 108
TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 108
TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 109
TABLE 21 MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 114
TABLE 22 MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 114
TABLE 23 MULTIOMICS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 115
TABLE 24 NORTH AMERICA: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 115
TABLE 25 EUROPE: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 115
TABLE 26 ASIA PACIFIC: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 116
TABLE 27 LATIN AMERICA: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 116
TABLE 28 MIDDLE EAST: MULTIOMICS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 116
TABLE 29 GCC COUNTRIES: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 117
TABLE 30 MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 117
TABLE 31 MULTIOMICS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 118
TABLE 32 NORTH AMERICA: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 118
TABLE 33 EUROPE: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 118
TABLE 34 ASIA PACIFIC: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 119
TABLE 35 LATIN AMERICA: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 119
TABLE 36 MIDDLE EAST: MULTIOMICS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 119
TABLE 37 GCC COUNTRIES: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 120
TABLE 38 ASSAY KITS & REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 120
TABLE 39 NORTH AMERICA: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 40 EUROPE: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 41 ASIA PACIFIC: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 42 LATIN AMERICA: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 122
TABLE 43 MIDDLE EAST: ASSAY KITS & REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 122
TABLE 44 GCC COUNTRIES: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 122
TABLE 45 OTHER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 123
TABLE 46 NORTH AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 123
TABLE 47 EUROPE: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 123
TABLE 48 ASIA PACIFIC: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 124
TABLE 49 LATIN AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 124
TABLE 50 MIDDLE EAST: OTHER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 124
TABLE 51 GCC COUNTRIES: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 125
TABLE 52 MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2024–2031 (USD MILLION) 126
TABLE 53 NORTH AMERICA: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 126
TABLE 54 EUROPE: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 126
TABLE 55 ASIA PACIFIC: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 56 LATIN AMERICA: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 57 MIDDLE EAST: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2024–2031 (USD MILLION) 127
TABLE 58 GCC COUNTRIES: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 59 MULTIOMICS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 129
TABLE 60 NORTH AMERICA: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 61 EUROPE: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 62 ASIA PACIFIC: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 63 LATIN AMERICA: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 64 MIDDLE EAST: MULTIOMICS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 130
TABLE 65 GCC COUNTRIES: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 66 MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 133
TABLE 67 SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 134
TABLE 68 SEQUENCING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 134
TABLE 69 NORTH AMERICA: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 70 EUROPE: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 71 ASIA PACIFIC: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 72 LATIN AMERICA: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 73 MIDDLE EAST: SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 136
TABLE 74 GCC COUNTRIES: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 75 LONG-READ SEQUENCING TECHNOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 137
TABLE 76 LONG-READ SEQUENCING TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 137
TABLE 77 NORTH AMERICA: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 78 EUROPE: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 79 ASIA PACIFIC: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 80 LATIN AMERICA: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 81 MIDDLE EAST: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 139
TABLE 82 GCC COUNTRIES: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 83 NANOPORE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 140
TABLE 84 NORTH AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 85 EUROPE: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 86 ASIA PACIFIC: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 87 LATIN AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 88 MIDDLE EAST: NANOPORE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 141
TABLE 89 GCC COUNTRIES: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 90 SMRT SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 143
TABLE 91 NORTH AMERICA: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 92 EUROPE: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 93 ASIA PACIFIC: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 94 LATIN AMERICA: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 95 MIDDLE EAST: SMRT SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 144
TABLE 96 GCC COUNTRIES: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 97 OTHER SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 145
TABLE 98 NORTH AMERICA: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 99 EUROPE: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 100 ASIA PACIFIC: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 101 LATIN AMERICA: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 102 MIDDLE EAST: OTHER SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 147
TABLE 103 GCC COUNTRIES: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 104 PROTEOMICS TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 149
TABLE 105 NORTH AMERICA: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 106 EUROPE: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 107 ASIA PACIFIC: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 108 LATIN AMERICA: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 109 MIDDLE EAST: PROTEOMICS TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 150
TABLE 110 GCC COUNTRIES: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 111 OTHER TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 151
TABLE 112 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152
TABLE 113 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152
TABLE 114 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152
TABLE 115 LATIN AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 116 MIDDLE EAST: OTHER TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 153
TABLE 117 GCC COUNTRIES: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 118 MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 155
TABLE 119 SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 156
TABLE 120 SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 156
TABLE 121 NORTH AMERICA: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 122 EUROPE: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 123 ASIA PACIFIC: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 124 LATIN AMERICA: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 125 MIDDLE EAST: SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 158
TABLE 126 GCC COUNTRIES: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 127 SINGLE-CELL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 159
TABLE 128 NORTH AMERICA: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 129 EUROPE: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 130 ASIA PACIFIC: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 131 LATIN AMERICA: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 132 MIDDLE EAST: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 160
TABLE 133 GCC COUNTRIES: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 161
TABLE 134 SINGLE-CELL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 161
TABLE 135 NORTH AMERICA: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 136 EUROPE: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 137 ASIA PACIFIC: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 163
TABLE 138 LATIN AMERICA: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 163
TABLE 139 MIDDLE EAST: SINGLE-CELL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 163
TABLE 140 GCC COUNTRIES: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 141 SINGLE-CELL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 164
TABLE 142 NORTH AMERICA: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 143 EUROPE: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 144 ASIA PACIFIC: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 145 LATIN AMERICA: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 146 MIDDLE EAST: SINGLE-CELL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 166
TABLE 147 GCC COUNTRIES: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 148 SINGLE-CELL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 167
TABLE 149 NORTH AMERICA: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 150 EUROPE: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 151 ASIA PACIFIC: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 152 LATIN AMERICA: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 153 MIDDLE EAST: SINGLE-CELL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 169
TABLE 154 GCC COUNTRIES: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 169
TABLE 155 OTHER SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 170
TABLE 156 NORTH AMERICA: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 157 EUROPE: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 158 ASIA PACIFIC: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 159 LATIN AMERICA: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 160 MIDDLE EAST: OTHER SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 171
TABLE 161 GCC COUNTRIES: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 162 PROTEOMICS METHOD MARKET, BY TYPE, 2024–2031 (USD MILLION) 172
TABLE 163 PROTEOMICS METHOD MARKET, BY REGION, 2024–2031 (USD MILLION) 173
TABLE 164 NORTH AMERICA: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 165 EUROPE: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 166 ASIA PACIFIC: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 167 LATIN AMERICA: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 168 MIDDLE EAST: PROTEOMICS METHOD MARKET, BY REGION, 2024–2031 (USD MILLION) 174
TABLE 169 GCC COUNTRIES: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 170 MS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 175
TABLE 171 NORTH AMERICA: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 172 EUROPE: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 173 ASIA PACIFIC: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 174 LATIN AMERICA: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 175 MIDDLE EAST: MS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 177
TABLE 176 GCC COUNTRIES: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 177 NGS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 178
TABLE 178 NORTH AMERICA: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 179 EUROPE: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 180 ASIA PACIFIC: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 181 LATIN AMERICA: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 182 MIDDLE EAST: NGS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 180
TABLE 183 GCC COUNTRIES: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 184 PCR-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 181
TABLE 185 NORTH AMERICA: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 186 EUROPE: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 187 ASIA PACIFIC: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 188 LATIN AMERICA: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 189 MIDDLE EAST: PCR-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 182
TABLE 190 GCC COUNTRIES: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 191 OTHER PROTEOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION) 183
TABLE 192 NORTH AMERICA: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 193 EUROPE: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 194 ASIA PACIFIC: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 195 LATIN AMERICA: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 196 MIDDLE EAST: OTHER PROTEOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION) 185
TABLE 197 GCC COUNTRIES: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 198 SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 186
TABLE 199 SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 187
TABLE 200 NORTH AMERICA: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 201 EUROPE: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 202 ASIA PACIFIC: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 203 LATIN AMERICA: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 204 MIDDLE EAST: SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 188
TABLE 205 GCC COUNTRIES: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 206 SPATIAL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 189
TABLE 207 NORTH AMERICA: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 208 EUROPE: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 209 ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 210 LATIN AMERICA: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 211 MIDDLE EAST: SPATIAL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 191
TABLE 212 GCC COUNTRIES: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 213 SPATIAL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 192
TABLE 214 NORTH AMERICA: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 215 EUROPE: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 216 ASIA PACIFIC: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 217 LATIN AMERICA: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 218 MIDDLE EAST: SPATIAL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 194
TABLE 219 GCC COUNTRIES: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 220 SPATIAL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 195
TABLE 221 NORTH AMERICA: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 195
TABLE 222 EUROPE: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 195
TABLE 223 ASIA PACIFIC: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 196
TABLE 224 LATIN AMERICA: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 196
TABLE 225 MIDDLE EAST: SPATIAL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 196
TABLE 226 GCC COUNTRIES: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 197
TABLE 227 SPATIAL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 197
TABLE 228 NORTH AMERICA: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 198
TABLE 229 EUROPE: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 198
TABLE 230 ASIA PACIFIC: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 198
TABLE 231 LATIN AMERICA: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 232 MIDDLE EAST: SPATIAL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 199
TABLE 233 GCC COUNTRIES: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 234 OTHER SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 200
TABLE 235 NORTH AMERICA: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 236 EUROPE: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 237 ASIA PACIFIC: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 238 LATIN AMERICA: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 239 MIDDLE EAST: OTHER SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 201
TABLE 240 GCC COUNTRIES: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 241 LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 202
TABLE 242 LONG-READ & LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 203
TABLE 243 NORTH AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 203
TABLE 244 EUROPE: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 203
TABLE 245 ASIA PACIFIC: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 246 LATIN AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 247 MIDDLE EAST: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 204
TABLE 248 GCC COUNTRIES: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 249 LONG-READ SEQUENCING METHOD MARKET, BY REGION, 2024–2031 (USD MILLION) 205
TABLE 250 NORTH AMERICA: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 251 EUROPE: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 252 ASIA PACIFIC: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 253 LATIN AMERICA: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 254 MIDDLE EAST: LONG-READ SEQUENCING METHOD MARKET, BY REGION, 2024–2031 (USD MILLION) 207
TABLE 255 GCC COUNTRIES: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 256 LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 208
TABLE 257 NORTH AMERICA: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 258 EUROPE: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 259 ASIA PACIFIC: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 260 LATIN AMERICA: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 261 MIDDLE EAST: LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 210
TABLE 262 GCC COUNTRIES: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 263 OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY REGION, 2024–2031 (USD MILLION) 211
TABLE 264 NORTH AMERICA: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 265 EUROPE: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 266 ASIA PACIFIC: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 267 LATIN AMERICA: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 268 MIDDLE EAST: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY REGION, 2024–2031 (USD MILLION) 212
TABLE 269 GCC COUNTRIES: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 213
TABLE 270 EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 213
TABLE 271 EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 214
TABLE 272 NORTH AMERICA: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 273 EUROPE: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 274 ASIA PACIFIC: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 275 LATIN AMERICA: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 276 MIDDLE EAST: EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 215
TABLE 277 GCC COUNTRIES: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 278 SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 216
TABLE 279 SEQUENCING-BASED EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 217
TABLE 280 NORTH AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 217
TABLE 281 EUROPE: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 217
TABLE 282 ASIA PACIFIC: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 283 LATIN AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 284 MIDDLE EAST: SEQUENCING-BASED EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 218
TABLE 285 GCC COUNTRIES: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 219
TABLE 286 DNA METHYLATION SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 219
TABLE 287 NORTH AMERICA: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 220
TABLE 288 EUROPE: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 220
TABLE 289 ASIA PACIFIC: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 290 LATIN AMERICA: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 291 MIDDLE EAST: DNA METHYLATION SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 221
TABLE 292 GCC COUNTRIES: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 293 CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 222
TABLE 294 NORTH AMERICA: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 295 EUROPE: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 296 ASIA PACIFIC: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 297 LATIN AMERICA: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 298 MIDDLE EAST: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 224
TABLE 299 GCC COUNTRIES: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 300 HISTONE MODIFICATION PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION) 225
TABLE 301 NORTH AMERICA: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 226
TABLE 302 EUROPE: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 226
TABLE 303 ASIA PACIFIC: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 304 LATIN AMERICA: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 305 MIDDLE EAST: HISTONE MODIFICATION PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION) 227
TABLE 306 GCC COUNTRIES: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 228
TABLE 307 CHROMATIN INTERACTION ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION) 228
TABLE 308 NORTH AMERICA: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 229
TABLE 309 EUROPE: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 229
TABLE 310 ASIA PACIFIC: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 230
TABLE 311 LATIN AMERICA: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 230
TABLE 312 MIDDLE EAST: CHROMATIN INTERACTION ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION) 230
TABLE 313 GCC COUNTRIES: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 314 OTHER EPIGENOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION) 231
TABLE 315 NORTH AMERICA: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 316 EUROPE: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 317 ASIA PACIFIC: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 318 LATIN AMERICA: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 233
TABLE 319 MIDDLE EAST: OTHER EPIGENOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION) 233
TABLE 320 GCC COUNTRIES: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 233
TABLE 321 OTHER METHODS MARKET, BY REGION, 2024–2031 (USD MILLION) 234
TABLE 322 NORTH AMERICA: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 234
TABLE 323 EUROPE: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 324 ASIA PACIFIC: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 325 LATIN AMERICA: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 326 MIDDLE EAST: OTHER METHODS MARKET, BY REGION, 2024–2031 (USD MILLION) 236
TABLE 327 GCC COUNTRIES: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 236
TABLE 328 MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 238
TABLE 329 SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY REGION, 2024–2031 (USD MILLION) 239
TABLE 330 NORTH AMERICA: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 331 EUROPE: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 332 ASIA PACIFIC: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 240
TABLE 333 LATIN AMERICA: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 240
TABLE 334 MIDDLE EAST: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY REGION, 2024–2031 (USD MILLION) 240
TABLE 335 GCC COUNTRIES: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 241
TABLE 336 SAMPLE PREPARATION MARKET, BY REGION, 2024–2031 (USD MILLION) 242
TABLE 337 NORTH AMERICA: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 338 EUROPE: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 339 ASIA PACIFIC: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 243
TABLE 340 LATIN AMERICA: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 243
TABLE 341 MIDDLE EAST: SAMPLE PREPARATION MARKET, BY REGION, 2024–2031 (USD MILLION) 243
TABLE 342 GCC COUNTRIES: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 244
TABLE 343 DATA VISUALIZATION & ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION) 245
TABLE 344 NORTH AMERICA: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 245
TABLE 345 EUROPE: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 245
TABLE 346 ASIA PACIFIC: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 246
TABLE 347 LATIN AMERICA: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 246
TABLE 348 MIDDLE EAST: DATA VISUALIZATION & ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION) 246
TABLE 349 GCC COUNTRIES: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 247
TABLE 350 MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 249
TABLE 351 ONCOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 250
TABLE 352 NORTH AMERICA: ONCOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 250
TABLE 353 EUROPE: ONCOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 250
TABLE 354 ASIA PACIFIC: ONCOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 251
TABLE 355 LATIN AMERICA: ONCOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 251
TABLE 356 MIDDLE EAST: ONCOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 251
TABLE 357 GCC COUNTRIES: ONCOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 252
TABLE 358 DRUG DISCOVERY & DEVELOPMENT MARKET, BY REGION, 2024–2031 (USD MILLION) 252
TABLE 359 NORTH AMERICA: DRUG DISCOVERY & DEVELOPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 253
TABLE 360 EUROPE: DRUG DISCOVERY & DEVELOPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 253
TABLE 361 ASIA PACIFIC: DRUG DISCOVERY & DEVELOPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 253
TABLE 362 LATIN AMERICA: DRUG DISCOVERY & DEVELOPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 254
TABLE 363 MIDDLE EAST: DRUG DISCOVERY & DEVELOPMENT MARKET, BY REGION, 2024–2031 (USD MILLION) 254
TABLE 364 GCC COUNTRIES: DRUG DISCOVERY & DEVELOPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 254
TABLE 365 IMMUNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 255
TABLE 366 NORTH AMERICA: IMMUNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 255
TABLE 367 EUROPE: IMMUNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 256
TABLE 368 ASIA PACIFIC: IMMUNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 256
TABLE 369 LATIN AMERICA: IMMUNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 256
TABLE 370 MIDDLE EAST: IMMUNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 257
TABLE 371 GCC COUNTRIES: IMMUNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 257
TABLE 372 PRECISION MEDICINE MARKET, BY REGION, 2024–2031 (USD MILLION) 258
TABLE 373 NORTH AMERICA: PRECISION MEDICINE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 258
TABLE 374 EUROPE: PRECISION MEDICINE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 258
TABLE 375 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 259
TABLE 376 LATIN AMERICA: PRECISION MEDICINE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 259
TABLE 377 MIDDLE EAST: PRECISION MEDICINE MARKET, BY REGION, 2024–2031 (USD MILLION) 259
TABLE 378 GCC COUNTRIES: PRECISION MEDICINE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 260
TABLE 379 BIOMARKER DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 261
TABLE 380 NORTH AMERICA: BIOMARKER DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 261
TABLE 381 EUROPE: BIOMARKER DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 261
TABLE 382 ASIA PACIFIC: BIOMARKER DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 262
TABLE 383 LATIN AMERICA: BIOMARKER DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 262
TABLE 384 MIDDLE EAST: BIOMARKER DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 262
TABLE 385 GCC COUNTRIES: BIOMARKER DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 263
TABLE 386 CELL BIOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 263
TABLE 387 NORTH AMERICA: CELL BIOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 264
TABLE 388 EUROPE: CELL BIOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 264
TABLE 389 ASIA PACIFIC: CELL BIOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 264
TABLE 390 LATIN AMERICA: CELL BIOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 265
TABLE 391 MIDDLE EAST: CELL BIOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 265
TABLE 392 GCC COUNTRIES: CELL BIOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 265
TABLE 393 TRANSLATIONAL RESEARCH MARKET, BY REGION, 2024–2031 (USD MILLION) 266
TABLE 394 NORTH AMERICA: TRANSLATIONAL RESEARCH MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 267
TABLE 395 EUROPE: TRANSLATIONAL RESEARCH MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 267
TABLE 396 ASIA PACIFIC: TRANSLATIONAL RESEARCH MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 267
TABLE 397 LATIN AMERICA: TRANSLATIONAL RESEARCH MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 268
TABLE 398 MIDDLE EAST: TRANSLATIONAL RESEARCH MARKET, BY REGION, 2024–2031 (USD MILLION) 268
TABLE 399 GCC COUNTRIES: TRANSLATIONAL RESEARCH MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 268
TABLE 400 NEUROLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 269
TABLE 401 NORTH AMERICA: NEUROLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 269
TABLE 402 EUROPE: NEUROLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 270
TABLE 403 ASIA PACIFIC: NEUROLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 270
TABLE 404 LATIN AMERICA: NEUROLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 270
TABLE 405 MIDDLE EAST: NEUROLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 271
TABLE 406 GCC COUNTRIES: NEUROLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 271
TABLE 407 CLINICAL DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION) 272
TABLE 408 NORTH AMERICA: CLINICAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 272
TABLE 409 EUROPE: CLINICAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 272
TABLE 410 ASIA PACIFIC: CLINICAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 273
TABLE 411 LATIN AMERICA: CLINICAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 273
TABLE 412 MIDDLE EAST: CLINICAL DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION) 273
TABLE 413 GCC COUNTRIES: CLINICAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 274
TABLE 414 OTHER APPLICATIONS MARKET, BY REGION, 2024–2031 (USD MILLION) 274
TABLE 415 NORTH AMERICA: OTHER APPLICATIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 275
TABLE 416 EUROPE: OTHER APPLICATIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 275
TABLE 417 ASIA PACIFIC: OTHER APPLICATIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 275
TABLE 418 LATIN AMERICA: OTHER APPLICATIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 276
TABLE 419 MIDDLE EAST: OTHER APPLICATIONS MARKET, BY REGION, 2024–2031 (USD MILLION) 276
TABLE 420 GCC COUNTRIES: OTHER APPLICATIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 276
TABLE 421 MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 278
TABLE 422 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY REGION, 2024–2031 (USD MILLION) 279
TABLE 423 NORTH AMERICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 279
TABLE 424 EUROPE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 279
TABLE 425 ASIA PACIFIC: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 280
TABLE 426 LATIN AMERICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 280
TABLE 427 MIDDLE EAST: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY REGION, 2024–2031 (USD MILLION) 280
TABLE 428 GCC COUNTRIES: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 281
TABLE 429 ACADEMIC & RESEARCH INSTITUTES MARKET, BY REGION, 2024–2031 (USD MILLION) 282
TABLE 430 NORTH AMERICA: ACADEMIC & RESEARCH INSTITUTES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 282
TABLE 431 EUROPE: ACADEMIC & RESEARCH INSTITUTES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 282
TABLE 432 ASIA PACIFIC: ACADEMIC & RESEARCH INSTITUTES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 283
TABLE 433 LATIN AMERICA: ACADEMIC & RESEARCH INSTITUTES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 283
TABLE 434 MIDDLE EAST: ACADEMIC & RESEARCH INSTITUTES MARKET, BY REGION, 2024–2031 (USD MILLION) 283
TABLE 435 GCC COUNTRIES: ACADEMIC & RESEARCH INSTITUTES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 284
TABLE 436 CROS & CDMOS MARKET, BY REGION, 2024–2031 (USD MILLION) 285
TABLE 437 NORTH AMERICA: CROS & CDMOS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 285
TABLE 438 EUROPE: CROS & CDMOS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 285
TABLE 439 ASIA PACIFIC: CROS & CDMOS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 286
TABLE 440 LATIN AMERICA: CROS & CDMOS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 286
TABLE 441 MIDDLE EAST: CROS & CDMOS MARKET, BY REGION, 2024–2031 (USD MILLION) 286
TABLE 442 GCC COUNTRIES: CROS & CDMOS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 287
TABLE 443 HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY REGION, 2024–2031 (USD MILLION) 287
TABLE 444 NORTH AMERICA: HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 288
TABLE 445 EUROPE: HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 288
TABLE 446 ASIA PACIFIC: HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 288
TABLE 447 LATIN AMERICA: HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 289
TABLE 448 MIDDLE EAST: HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY REGION, 2024–2031 (USD MILLION) 289
TABLE 449 GCC COUNTRIES: HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 289
TABLE 450 MULTIOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 291
TABLE 451 NORTH AMERICA: MULTIOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 292
TABLE 452 NORTH AMERICA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 293
TABLE 453 NORTH AMERICA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 293
TABLE 454 NORTH AMERICA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 293
TABLE 455 NORTH AMERICA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 294
TABLE 456 NORTH AMERICA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 294
TABLE 457 NORTH AMERICA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 294
TABLE 458 NORTH AMERICA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 295
TABLE 459 NORTH AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 295
TABLE 460 NORTH AMERICA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 295
TABLE 461 NORTH AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 296
TABLE 462 NORTH AMERICA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 296
TABLE 463 NORTH AMERICA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 296
TABLE 464 NORTH AMERICA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 297
TABLE 465 NORTH AMERICA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 297
TABLE 466 NORTH AMERICA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 297
TABLE 467 NORTH AMERICA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 298
TABLE 468 US: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 298
TABLE 469 US: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 299
TABLE 470 US: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 299
TABLE 471 US: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 299
TABLE 472 US: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 300
TABLE 473 US: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 300
TABLE 474 US: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 300
TABLE 475 US: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 301
TABLE 476 US: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 301
TABLE 477 US: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 301
TABLE 478 US: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 302
TABLE 479 US: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 302
TABLE 480 US: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 302
TABLE 481 US: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 303
TABLE 482 US: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 303
TABLE 483 US: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 304
TABLE 484 CANADA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 304
TABLE 485 CANADA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 305
TABLE 486 CANADA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 305
TABLE 487 CANADA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 305
TABLE 488 CANADA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 306
TABLE 489 CANADA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 306
TABLE 490 CANADA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 306
TABLE 491 CANADA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 307
TABLE 492 CANADA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 307
TABLE 493 CANADA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 307
TABLE 494 CANADA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 308
TABLE 495 CANADA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 308
TABLE 496 CANADA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 308
TABLE 497 CANADA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 309
TABLE 498 CANADA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 309
TABLE 499 CANADA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 310
TABLE 500 EUROPE: MULTIOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 311
TABLE 501 EUROPE: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 311
TABLE 502 EUROPE: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 311
TABLE 503 EUROPE: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 312
TABLE 504 EUROPE: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 312
TABLE 505 EUROPE: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 312
TABLE 506 EUROPE: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 313
TABLE 507 EUROPE: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 313
TABLE 508 EUROPE: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 313
TABLE 509 EUROPE: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 314
TABLE 510 EUROPE: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 314
TABLE 511 EUROPE: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 314
TABLE 512 EUROPE: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 315
TABLE 513 EUROPE: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 315
TABLE 514 EUROPE: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 315
TABLE 515 EUROPE: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 316
TABLE 516 EUROPE: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 316
TABLE 517 GERMANY: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 317
TABLE 518 GERMANY: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 317
TABLE 519 GERMANY: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 317
TABLE 520 GERMANY: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 318
TABLE 521 GERMANY: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 318
TABLE 522 GERMANY: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 318
TABLE 523 GERMANY: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 319
TABLE 524 GERMANY: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 319
TABLE 525 GERMANY: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 319
TABLE 526 GERMANY: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 320
TABLE 527 GERMANY: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 320
TABLE 528 GERMANY: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 320
TABLE 529 GERMANY: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 321
TABLE 530 GERMANY: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 321
TABLE 531 GERMANY: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 321
TABLE 532 GERMANY: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 322
TABLE 533 UK: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 322
TABLE 534 UK: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 323
TABLE 535 UK: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 323
TABLE 536 UK: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 323
TABLE 537 UK: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 324
TABLE 538 UK: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 324
TABLE 539 UK: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 324
TABLE 540 UK: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 325
TABLE 541 UK: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 325
TABLE 542 UK: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 325
TABLE 543 UK: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 326
TABLE 544 UK: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 326
TABLE 545 UK: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 326
TABLE 546 UK: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 326
TABLE 547 UK: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 327
TABLE 548 UK: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 327
TABLE 549 FRANCE: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 328
TABLE 550 FRANCE: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 328
TABLE 551 FRANCE: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 328
TABLE 552 FRANCE: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 329
TABLE 553 FRANCE: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 329
TABLE 554 FRANCE: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 329
TABLE 555 FRANCE: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 330
TABLE 556 FRANCE: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 330
TABLE 557 FRANCE: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 330
TABLE 558 FRANCE: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 331
TABLE 559 FRANCE: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 331
TABLE 560 FRANCE: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 331
TABLE 561 FRANCE: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 332
TABLE 562 FRANCE: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 332
TABLE 563 FRANCE: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 332
TABLE 564 FRANCE: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 333
TABLE 565 ITALY: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 333
TABLE 566 ITALY: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 334
TABLE 567 ITALY: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 334
TABLE 568 ITALY: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 334
TABLE 569 ITALY: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 335
TABLE 570 ITALY: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 335
TABLE 571 ITALY: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 335
TABLE 572 ITALY: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 336
TABLE 573 ITALY: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 336
TABLE 574 ITALY: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 336
TABLE 575 ITALY: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 337
TABLE 576 ITALY: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 337
TABLE 577 ITALY: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 337
TABLE 578 ITALY: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 337
TABLE 579 ITALY: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 338
TABLE 580 ITALY: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 338
TABLE 581 SPAIN: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 339
TABLE 582 SPAIN: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 339
TABLE 583 SPAIN: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 339
TABLE 584 SPAIN: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 340
TABLE 585 SPAIN: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 340
TABLE 586 SPAIN: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 340
TABLE 587 SPAIN: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 341
TABLE 588 SPAIN: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 341
TABLE 589 SPAIN: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 341
TABLE 590 SPAIN: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 342
TABLE 591 SPAIN: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 342
TABLE 592 SPAIN: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 342
TABLE 593 SPAIN: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 343
TABLE 594 SPAIN: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 343
TABLE 595 SPAIN: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 343
TABLE 596 SPAIN: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 344
TABLE 597 REST OF EUROPE: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 344
TABLE 598 REST OF EUROPE: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 345
TABLE 599 REST OF EUROPE: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 345
TABLE 600 REST OF EUROPE: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 345
TABLE 601 REST OF EUROPE: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 346
TABLE 602 REST OF EUROPE: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 346
TABLE 603 REST OF EUROPE: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 346
TABLE 604 REST OF EUROPE: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 347
TABLE 605 REST OF EUROPE: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 347
TABLE 606 REST OF EUROPE: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 347
TABLE 607 REST OF EUROPE: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 348
TABLE 608 REST OF EUROPE: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 348
TABLE 609 REST OF EUROPE: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 348
TABLE 610 REST OF EUROPE: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 349
TABLE 611 REST OF EUROPE: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 349
TABLE 612 REST OF EUROPE: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 349
TABLE 613 ASIA PACIFIC: MULTIOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 351
TABLE 614 ASIA PACIFIC: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 351
TABLE 615 ASIA PACIFIC: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 351
TABLE 616 ASIA PACIFIC: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 352
TABLE 617 ASIA PACIFIC: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 352
TABLE 618 ASIA PACIFIC: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 352
TABLE 619 ASIA PACIFIC: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 353
TABLE 620 ASIA PACIFIC: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 353
TABLE 621 ASIA PACIFIC: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 353
TABLE 622 ASIA PACIFIC: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 354
TABLE 623 ASIA PACIFIC: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 354
TABLE 624 ASIA PACIFIC: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 354
TABLE 625 ASIA PACIFIC: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 355
TABLE 626 ASIA PACIFIC: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 355
TABLE 627 ASIA PACIFIC: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 355
TABLE 628 ASIA PACIFIC: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 356
TABLE 629 ASIA PACIFIC: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 356
TABLE 630 CHINA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 357
TABLE 631 CHINA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 357
TABLE 632 CHINA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 358
TABLE 633 CHINA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 358
TABLE 634 CHINA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 358
TABLE 635 CHINA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 359
TABLE 636 CHINA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 359
TABLE 637 CHINA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 359
TABLE 638 CHINA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 360
TABLE 639 CHINA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 360
TABLE 640 CHINA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 360
TABLE 641 CHINA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 361
TABLE 642 CHINA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 361
TABLE 643 CHINA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 361
TABLE 644 CHINA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 362
TABLE 645 CHINA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 362
TABLE 646 JAPAN: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 363
TABLE 647 JAPAN: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 363
TABLE 648 JAPAN: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 364
TABLE 649 JAPAN: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 364
TABLE 650 JAPAN: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 364
TABLE 651 JAPAN: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 365
TABLE 652 JAPAN: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 365
TABLE 653 JAPAN: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 365
TABLE 654 JAPAN: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 366
TABLE 655 JAPAN: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 366
TABLE 656 JAPAN: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 366
TABLE 657 JAPAN: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 367
TABLE 658 JAPAN: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 367
TABLE 659 JAPAN: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 367
TABLE 660 JAPAN: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 368
TABLE 661 JAPAN: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 368
TABLE 662 SOUTH KOREA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 369
TABLE 663 SOUTH KOREA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 369
TABLE 664 SOUTH KOREA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 370
TABLE 665 SOUTH KOREA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 370
TABLE 666 SOUTH KOREA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 370
TABLE 667 SOUTH KOREA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 371
TABLE 668 SOUTH KOREA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 371
TABLE 669 SOUTH KOREA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 371
TABLE 670 SOUTH KOREA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 372
TABLE 671 SOUTH KOREA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 372
TABLE 672 SOUTH KOREA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 372
TABLE 673 SOUTH KOREA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 373
TABLE 674 SOUTH KOREA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 373
TABLE 675 SOUTH KOREA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 373
TABLE 676 SOUTH KOREA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 374
TABLE 677 SOUTH KOREA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 374
TABLE 678 INDIA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 375
TABLE 679 INDIA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 375
TABLE 680 INDIA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 375
TABLE 681 INDIA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 376
TABLE 682 INDIA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 376
TABLE 683 INDIA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 376
TABLE 684 INDIA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 377
TABLE 685 INDIA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 377
TABLE 686 INDIA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 377
TABLE 687 INDIA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 378
TABLE 688 INDIA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 378
TABLE 689 INDIA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 378
TABLE 690 INDIA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 379
TABLE 691 INDIA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 379
TABLE 692 INDIA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 379
TABLE 693 INDIA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 380
TABLE 694 AUSTRALIA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 381
TABLE 695 AUSTRALIA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 381
TABLE 696 AUSTRALIA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 381
TABLE 697 AUSTRALIA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 382
TABLE 698 AUSTRALIA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 382
TABLE 699 AUSTRALIA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 382
TABLE 700 AUSTRALIA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 383
TABLE 701 AUSTRALIA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 383
TABLE 702 AUSTRALIA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 383
TABLE 703 AUSTRALIA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 384
TABLE 704 AUSTRALIA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 384
TABLE 705 AUSTRALIA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 384
TABLE 706 AUSTRALIA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 385
TABLE 707 AUSTRALIA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 385
TABLE 708 AUSTRALIA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 385
TABLE 709 AUSTRALIA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 386
TABLE 710 REST OF ASIA PACIFIC: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 386
TABLE 711 REST OF ASIA PACIFIC: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 387
TABLE 712 REST OF ASIA PACIFIC: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 387
TABLE 713 REST OF ASIA PACIFIC: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 387
TABLE 714 REST OF ASIA PACIFIC: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 388
TABLE 715 REST OF ASIA PACIFIC: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 388
TABLE 716 REST OF ASIA PACIFIC: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 388
TABLE 717 REST OF ASIA PACIFIC: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 389
TABLE 718 REST OF ASIA PACIFIC: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 389
TABLE 719 REST OF ASIA PACIFIC: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 389
TABLE 720 REST OF ASIA PACIFIC: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 390
TABLE 721 REST OF ASIA PACIFIC: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 390
TABLE 722 REST OF ASIA PACIFIC: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 390
TABLE 723 REST OF ASIA PACIFIC: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 391
TABLE 724 REST OF ASIA PACIFIC: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 391
TABLE 725 REST OF ASIA PACIFIC: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 392
TABLE 726 LATIN AMERICA: MULTIOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 392
TABLE 727 LATIN AMERICA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 393
TABLE 728 LATIN AMERICA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 393
TABLE 729 LATIN AMERICA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 393
TABLE 730 LATIN AMERICA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 394
TABLE 731 LATIN AMERICA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 394
TABLE 732 LATIN AMERICA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 394
TABLE 733 LATIN AMERICA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 395
TABLE 734 LATIN AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 395
TABLE 735 LATIN AMERICA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 395
TABLE 736 LATIN AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 396
TABLE 737 LATIN AMERICA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 396
TABLE 738 LATIN AMERICA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 396
TABLE 739 LATIN AMERICA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 397
TABLE 740 LATIN AMERICA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 397
TABLE 741 LATIN AMERICA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 397
TABLE 742 LATIN AMERICA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 398
TABLE 743 BRAZIL: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 398
TABLE 744 BRAZIL: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 398
TABLE 745 BRAZIL: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 399
TABLE 746 BRAZIL: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 399
TABLE 747 BRAZIL: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 399
TABLE 748 BRAZIL: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 400
TABLE 749 BRAZIL: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 400
TABLE 750 BRAZIL: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 400
TABLE 751 BRAZIL: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 401
TABLE 752 BRAZIL: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 401
TABLE 753 BRAZIL: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 401
TABLE 754 BRAZIL: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 402
TABLE 755 BRAZIL: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 402
TABLE 756 BRAZIL: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 402
TABLE 757 BRAZIL: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 403
TABLE 758 BRAZIL: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 403
TABLE 759 REST OF LATIN AMERICA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 404
TABLE 760 REST OF LATIN AMERICA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 404
TABLE 761 REST OF LATIN AMERICA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 404
TABLE 762 REST OF LATIN AMERICA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 405
TABLE 763 REST OF LATIN AMERICA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 405
TABLE 764 REST OF LATIN AMERICA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 405
TABLE 765 REST OF LATIN AMERICA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 406
TABLE 766 REST OF LATIN AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 406
TABLE 767 REST OF LATIN AMERICA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 406
TABLE 768 REST OF LATIN AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 407
TABLE 769 REST OF LATIN AMERICA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 407
TABLE 770 REST OF LATIN AMERICA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 407
TABLE 771 REST OF LATIN AMERICA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 408
TABLE 772 REST OF LATIN AMERICA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 408
TABLE 773 REST OF LATIN AMERICA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 408
TABLE 774 REST OF LATIN AMERICA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 409
TABLE 775 MIDDLE EAST: MULTIOMICS MARKET, BY REGION, 2024–2031 (USD MILLION) 409
TABLE 776 MIDDLE EAST: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 410
TABLE 777 MIDDLE EAST: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 410
TABLE 778 MIDDLE EAST: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 410
TABLE 779 MIDDLE EAST: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 411
TABLE 780 MIDDLE EAST: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 411
TABLE 781 MIDDLE EAST: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 411
TABLE 782 MIDDLE EAST: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 412
TABLE 783 MIDDLE EAST: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 412
TABLE 784 MIDDLE EAST: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 412
TABLE 785 MIDDLE EAST: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 413
TABLE 786 MIDDLE EAST: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 413
TABLE 787 MIDDLE EAST: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 413
TABLE 788 MIDDLE EAST: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 414
TABLE 789 MIDDLE EAST: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 414
TABLE 790 MIDDLE EAST: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 414
TABLE 791 MIDDLE EAST: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 415
TABLE 792 GCC COUNTRIES: MULTIOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 415
TABLE 793 GCC COUNTRIES: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 416
TABLE 794 GCC COUNTRIES: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 416
TABLE 795 GCC COUNTRIES: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 416
TABLE 796 GCC COUNTRIES: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 417
TABLE 797 GCC COUNTRIES: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 417
TABLE 798 GCC COUNTRIES: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 417
TABLE 799 GCC COUNTRIES: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 418
TABLE 800 GCC COUNTRIES: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 418
TABLE 801 GCC COUNTRIES: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 418
TABLE 802 GCC COUNTRIES: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 419
TABLE 803 GCC COUNTRIES: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 419
TABLE 804 GCC COUNTRIES: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 419
TABLE 805 GCC COUNTRIES: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 420
TABLE 806 GCC COUNTRIES: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 420
TABLE 807 GCC COUNTRIES: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 420
TABLE 808 GCC COUNTRIES: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 421
TABLE 809 SAUDI ARABIA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 421
TABLE 810 SAUDI ARABIA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 422
TABLE 811 SAUDI ARABIA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 422
TABLE 812 SAUDI ARABIA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 422
TABLE 813 SAUDI ARABIA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 423
TABLE 814 SAUDI ARABIA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 423
TABLE 815 SAUDI ARABIA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 423
TABLE 816 SAUDI ARABIA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 424
TABLE 817 SAUDI ARABIA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 424
TABLE 818 SAUDI ARABIA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 424
TABLE 819 SAUDI ARABIA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 425
TABLE 820 SAUDI ARABIA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 425
TABLE 821 SAUDI ARABIA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 425
TABLE 822 SAUDI ARABIA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 426
TABLE 823 SAUDI ARABIA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 426
TABLE 824 SAUDI ARABIA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 427
TABLE 825 UAE: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 427
TABLE 826 UAE: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 428
TABLE 827 UAE: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 428
TABLE 828 UAE: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 428
TABLE 829 UAE: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 429
TABLE 830 UAE: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 429
TABLE 831 UAE: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 429
TABLE 832 UAE: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 430
TABLE 833 UAE: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 430
TABLE 834 UAE: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 430
TABLE 835 UAE: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 431
TABLE 836 UAE: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 431
TABLE 837 UAE: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 431
TABLE 838 UAE: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 432
TABLE 839 UAE: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 432
TABLE 840 UAE: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 433
TABLE 841 REST OF GCC COUNTRIES: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 433
TABLE 842 REST OF GCC COUNTRIES: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 434
TABLE 843 REST OF GCC COUNTRIES: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 434
TABLE 844 REST OF GCC COUNTRIES: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 434
TABLE 845 REST OF GCC COUNTRIES: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 435
TABLE 846 REST OF GCC COUNTRIES: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 435
TABLE 847 REST OF GCC COUNTRIES: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 435
TABLE 848 REST OF GCC COUNTRIES: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 436
TABLE 849 REST OF GCC COUNTRIES: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 436
TABLE 850 REST OF GCC COUNTRIES: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 436
TABLE 851 REST OF GCC COUNTRIES: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 437
TABLE 852 REST OF GCC COUNTRIES: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 437
TABLE 853 REST OF GCC COUNTRIES: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 437
TABLE 854 REST OF GCC COUNTRIES: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 438
TABLE 855 REST OF GCC COUNTRIES: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 438
TABLE 856 REST OF GCC COUNTRIES: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 439
TABLE 857 REST OF MIDDLE EAST: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 439
TABLE 858 REST OF MIDDLE EAST: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 440
TABLE 859 REST OF MIDDLE EAST: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 440
TABLE 860 REST OF MIDDLE EAST: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 440
TABLE 861 REST OF MIDDLE EAST: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 441
TABLE 862 REST OF MIDDLE EAST: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 441
TABLE 863 REST OF MIDDLE EAST: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 441
TABLE 864 REST OF MIDDLE EAST: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 442
TABLE 865 REST OF MIDDLE EAST: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 442
TABLE 866 REST OF MIDDLE EAST: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 442
TABLE 867 REST OF MIDDLE EAST: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 443
TABLE 868 REST OF MIDDLE EAST: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 443
TABLE 869 REST OF MIDDLE EAST: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 443
TABLE 870 REST OF MIDDLE EAST: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 444
TABLE 871 REST OF MIDDLE EAST: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 444
TABLE 872 REST OF MIDDLE EAST: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 445
TABLE 873 AFRICA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 445
TABLE 874 AFRICA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 446
TABLE 875 AFRICA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 446
TABLE 876 AFRICA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 446
TABLE 877 AFRICA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 447
TABLE 878 AFRICA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 447
TABLE 879 AFRICA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 447
TABLE 880 AFRICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION) 448
TABLE 881 AFRICA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 448
TABLE 882 AFRICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 448
TABLE 883 AFRICA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 449
TABLE 884 AFRICA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 449
TABLE 885 AFRICA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION) 449
TABLE 886 AFRICA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION) 449
TABLE 887 AFRICA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 450
TABLE 888 AFRICA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION) 450
TABLE 889 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS 451
TABLE 890 MULTIOMICS MARKET: DEGREE OF COMPETITION 454
TABLE 891 MULTIOMICS MARKET: REGION FOOTPRINT 459
TABLE 892 MULTIOMICS MARKET: OFFERING FOOTPRINT 459
TABLE 893 MULTIOMICS MARKET: TECHNOLOGY FOOTPRINT 460
TABLE 894 MULTIOMICS MARKET: WORKFLOW FOOTPRINT 461
TABLE 895 MULTIOMICS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 464
TABLE 896 MULTIOMICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 465
TABLE 897 MULTIOMICS MARKET: PRODUCT & SERVICE LAUNCHES,
JANUARY 2023–JULY 2026 468
TABLE 898 MULTIOMICS MARKET: DEALS, JANUARY 2023–JULY 2026 468
TABLE 899 MULTIOMICS MARKET: EXPANSIONS, JANUARY 2023–JULY 2026 469
TABLE 900 10X GENOMICS: COMPANY OVERVIEW 470
TABLE 901 10X GENOMICS: PRODUCTS & SERVICES OFFERED 471
TABLE 902 10X GENOMICS, INC.: PRODUCT & SERVICE LAUNCHES,
JANUARY 2023–JULY 2026 473
TABLE 903 10X GENOMICS, INC.: DEALS, JANUARY 2023–JULY 2026 473
TABLE 904 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 475
TABLE 905 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED 476
TABLE 906 THERMO FISHER SCIENTIFIC INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026 478
TABLE 907 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–JULY 2026 479
TABLE 908 ILLUMINA, INC.: COMPANY OVERVIEW 481
TABLE 909 ILLUMINA, INC.: PRODUCTS & SERVICES OFFERED 482
TABLE 910 ILLUMINA, INC: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026 484
TABLE 911 ILLUMINA, INC.: DEALS, JANUARY 2023–JULY 2026 484
TABLE 912 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW 486
TABLE 913 OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCTS & SERVICES OFFERED 487
TABLE 914 OXFORD NANOPORE TECHNOLOGIES PLC: DEALS, JANUARY 2023–JULY 2026 488
TABLE 915 OXFORD NANOPORE TECHNOLOGIES PLC: EXPANSIONS,
JANUARY 2023–JULY 2026 489
TABLE 916 BRUKER: COMPANY OVERVIEW 491
TABLE 917 BRUKER: PRODUCTS & SERVICES OFFERED 492
TABLE 918 BRUKER : PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026 494
TABLE 919 BRUKER : DEALS, JANUARY 2023–JULY 2026 495
TABLE 920 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: COMPANY OVERVIEW 496
TABLE 921 PACBIO.: PRODUCTS & SERVICES OFFERED 497
TABLE 922 PACBIO.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026 499
TABLE 923 PACBIO.: DEALS, JANUARY 2023–JULY 2026 499
TABLE 924 DANAHER CORPORATION: COMPANY OVERVIEW 501
TABLE 925 DANAHER CORPORATION: PRODUCTS & SERVICES OFFERED 502
TABLE 926 DANAHER CORPORATION: PRODUCT & SERVICE LAUNCHES,
JANUARY 2023–JULY 2026 504
TABLE 927 DANAHER CORPORATION: DEALS, JANUARY 2023–JULY 2026 505
TABLE 928 VIZGEN, INC.: COMPANY OVERVIEW 506
TABLE 929 VIZGEN, INC.: PRODUCTS & SERVICES OFFERED 506
TABLE 930 VIZGEN, INC.: DEALS, JANUARY 2023–JULY 2026 508
TABLE 931 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 509
TABLE 932 AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED 510
TABLE 933 AGILENT TECHNOLOGIES, INC.: PRODUCT & SERVICE LAUNCHES,
JANUARY 2023–JULY 2026 513
TABLE 934 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023–JULY 2026 513
TABLE 935 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2023–JULY 2026 514
TABLE 936 BIOGNOSYS: COMPANY OVERVIEW 515
TABLE 937 BIOGNOSYS: PRODUCTS & SERVICES OFFERED 515
TABLE 938 BIOGNOSYS: DEALS, JANUARY 2023–JULY 2026 516
TABLE 939 MERCK KGAA: COMPANY OVERVIEW 517
TABLE 940 MERCK KGAA: PRODUCTS & SERVICES OFFERED 518
TABLE 941 MERCK KGAA: EXPANSIONS, JANUARY 2023–JULY 2026 520
TABLE 942 QIAGEN: COMPANY OVERVIEW 521
TABLE 943 QIAGEN: PRODUCTS & SERVICES OFFERED 522
TABLE 944 QIAGEN: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026 523
TABLE 945 QIAGEN: DEALS, JANUARY 2023–JULY 2026 524
TABLE 946 QIAGEN: EXPANSIONS, JANUARY 2023–JULY 2026 524
TABLE 947 REVVITY: COMPANY OVERVIEW 525
TABLE 948 REVVITY: PRODUCTS & SERVICES OFFERED 526
TABLE 949 REVVITY: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026 528
TABLE 950 REVVITY: DEALS, JANUARY 2023–JULY 2026 528
TABLE 951 WATERS CORPORATION: COMPANY OVERVIEW 530
TABLE 952 WATERS CORPORATION: PRODUCTS & SERVICES OFFERED 531
TABLE 953 WATERS CORPORATION: PRODUCT & SERVICE LAUNCHES,
JANUARY 2023–JULY 2026 532
TABLE 954 WATERS CORPORATION: DEALS, JANUARY 2023–JULY 2026 533
TABLE 955 WATERS CORPORATION: EXPANSIONS, JANUARY 2023–JULY 2026 534
TABLE 956 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 535
TABLE 957 BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED 536
TABLE 958 BIO-RAD LABORATORIES, INC.: PRODUCT & SERVICE LAUNCHES,
JANUARY 2023–JULY 2026 537
TABLE 959 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2023–JULY 2026 538
TABLE 960 TAKARA BIO INC.: COMPANY OVERVIEW 539
TABLE 961 TAKARA BIO INC.: PRODUCTS & SERVICES OFFERED 540
TABLE 962 TAKARA BIO INC.: EXPANSIONS, JANUARY 2023–JULY 2026 542
TABLE 963 METABOLON, INC.: COMPANY OVERVIEW 543
TABLE 964 METABOLON, INC.: PRODUCTS & SERVICES OFFERED 543
TABLE 965 METABOLON, INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026 544
TABLE 966 BGI GENOMICS CO., LTD.: COMPANY OVERVIEW 545
TABLE 967 NOVOGENE CO., LTD.: COMPANY OVERVIEW 546
TABLE 968 AZENTA, INC.: COMPANY OVERVIEW 548
TABLE 969 EVOTEC SE: COMPANY OVERVIEW 549
TABLE 970 MEDGENOME LABS LTD.: COMPANY OVERVIEW 550
TABLE 971 CD GENOMICS: COMPANY OVERVIEW 551
TABLE 972 BIOGENITY: COMPANY OVERVIEW 552
TABLE 973 SAPIENT BIOANALYTICS, LLC: COMPANY OVERVIEW 553
TABLE 974 RAYBIOTECH, INC.: COMPANY OVERVIEW 554
TABLE 975 SOURCE BIOSCIENCE LTD.: COMPANY OVERVIEW 555
TABLE 976 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 564
FIGURE 1 MARKETS COVERED AND REGIONS CONSIDERED 54
FIGURE 2 MARKET SCENARIO 59
FIGURE 3 GLOBAL MULTIOMICS MARKET, 2024–2031 59
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN
MULTIOMICS MARKET, 2023–2026 60
FIGURE 5 DISRUPTIONS INFLUENCING THE GROWTH OF MULTIOMICS MARKET 61
FIGURE 6 HIGH-GROWTH SEGMENTS IN MULTIOMICS MARKET, 2026–2031 62
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN MULTIOMICS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 63
FIGURE 8 RAPID ADOPTION OF SINGLE-CELL AND SPATIAL MULTIOMICS TO DRIVE MARKET 64
FIGURE 9 PRODUCTS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2025 65
FIGURE 10 INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 66
FIGURE 11 PRODUCTS TO DOMINATE MARKET DURING FORECAST PERIOD 66
FIGURE 12 MULTIOMICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 67
FIGURE 13 MULTIOMICS MARKET: PORTERS FIVE FORCES ANALYSIS 75
FIGURE 14 MULTIOMICS MARKET: VALUE CHAIN ANALYSIS 79
FIGURE 15 MULTIOMICS MARKET: ECOSYSTEM ANALYSIS 80
FIGURE 16 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY TYPE, 2023–2025 (USD) 82
FIGURE 17 AVERAGE SELLING PRICE OF CONSUMABLES, 2023– 2025 (USD) 83
FIGURE 18 AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2025 (USD) 84
FIGURE 19 AVERAGE SELLING PRICE OF CONSUMABLES, BY REGION, 2025 (USD) 85
FIGURE 20 MULTIOMICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 89
FIGURE 21 INVESTMENT/FUNDING ACTIVITY IN MULTIOMICS MARKET 90
FIGURE 22 TOP APPLICANTS/OWNERS (COMPANIES) FOR MULTIOMICS PATENTS, 2015–2025 101
FIGURE 23 IMPACT OF AI/GEN AI ON MULTIOMICS MARKET 103
FIGURE 24 NORTH AMERICA: MULTIOMICS MARKET SNAPSHOT 292
FIGURE 25 ASIA PACIFIC: MULTIOMICS MARKET SNAPSHOT 350
FIGURE 26 REVENUE ANALYSIS OF KEY PLAYERS, 2021–2025 (USD MILLION) 453
FIGURE 27 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025 454
FIGURE 28 MULTIOMICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 457
FIGURE 29 MULTIOMICS MARKET: COMPANY FOOTPRINT 458
FIGURE 30 MULTIOMICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 463
FIGURE 31 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 466
FIGURE 32 EV/EBITDA OF KEY VENDORS 466
FIGURE 33 MULTIOMICS MARKET: BRAND/PRODUCT COMPARISON 467
FIGURE 34 10X GENOMICS: COMPANY SNAPSHOT (2025) 471
FIGURE 35 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 476
FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT (2025) 482
FIGURE 37 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT (2025) 487
FIGURE 38 BRUKER: COMPANY SNAPSHOT (2025) 492
FIGURE 39 PACBIO.: COMPANY SNAPSHOT (2025) 497
FIGURE 40 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 502
FIGURE 41 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 510
FIGURE 42 MERCK KGAA: COMPANY SNAPSHOT (2025) 518
FIGURE 43 QIAGEN: COMPANY SNAPSHOT (2025) 521
FIGURE 44 REVVITY: COMPANY SNAPSHOT (2025) 526
FIGURE 45 WATERS CORPORATION: COMPANY SNAPSHOT (2025) 531
FIGURE 46 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 536
FIGURE 47 TAKARA BIO INC.: COMPANY SNAPSHOT (2025) 540
FIGURE 48 RESEARCH DESIGN 556
FIGURE 49 MULTIOMICS MARKET: BREAKDOWN OF PRIMARIES 558
FIGURE 50 MULTIOMICS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 559
FIGURE 51 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025 560
FIGURE 52 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF
THERMO FISHER SCIENTIFIC, INC. (2025) 560
FIGURE 53 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 562
FIGURE 54 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 562
FIGURE 55 MULTIOMICS MARKET CAGR PROJECTIONS 564
FIGURE 56 DATA TRIANGULATION METHODOLOGY 565
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們